Gapping up
In reaction to disappointing earnings/guidance:
- UNH +1.9%, JNJ +1.8%, BLK +1.4%, BAC +0.3%
Other news:
- JMIA +7.3% (after closing 25% higher on the day)
- KMDA +5.4% (receives letter from the FDA stating that the Company has satisfactorily addressed the concerns and questions regarding its Inhaled Alpha-1-Antitrypsin program for the treatment of Alpha-1 Antitrypsin Deficiency)
- CRSP +3.9% (CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated (VRTX) announce FDA Fast Track Designation for CTX001 for the treatment of transfusion-dependent beta thalassemia)
- APHA +2% (modestly rebounding from today's 15% decline)
- LPI +1.9% (Laredo Petroleum settled its previously disclosed litigation with Shell Trading)
- GILD +0.9% (Gilead Sciences and insitro enter strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis)
Analyst comments:
- ELF +5.7% (upgraded to Buy from Neutral at DA Davidson)
- ROKU +2.2% (positive note from Needham)
- NFLX +1.8% (upgraded to Buy from Hold at Deutsche Bank ahead of tonight's earnings)
- CMI +1.3% (upgraded to Buy from Neutral at Citigroup)
- MRO +1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)